Edgestream Partners L.P. cut its holdings in shares of Balchem Corporation (NASDAQ:BCPC - Free Report) by 37.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,645 shares of the basic materials company's stock after selling 17,170 shares during the period. Edgestream Partners L.P. owned about 0.09% of Balchem worth $4,755,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. CWM LLC grew its position in shares of Balchem by 34.0% during the first quarter. CWM LLC now owns 520 shares of the basic materials company's stock worth $86,000 after buying an additional 132 shares in the last quarter. Xponance Inc. grew its position in shares of Balchem by 5.8% during the first quarter. Xponance Inc. now owns 2,447 shares of the basic materials company's stock worth $406,000 after buying an additional 134 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in shares of Balchem by 160.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 53,300 shares of the basic materials company's stock worth $8,596,000 after buying an additional 32,800 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Balchem by 2.6% during the first quarter. Principal Financial Group Inc. now owns 169,226 shares of the basic materials company's stock worth $28,092,000 after buying an additional 4,311 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in shares of Balchem by 11.8% during the first quarter. Teacher Retirement System of Texas now owns 34,896 shares of the basic materials company's stock worth $5,793,000 after buying an additional 3,695 shares in the last quarter. 87.91% of the stock is currently owned by hedge funds and other institutional investors.
Balchem Price Performance
Shares of BCPC traded down $5.53 during trading hours on Friday, reaching $152.84. 232,035 shares of the company traded hands, compared to its average volume of 143,550. The company has a quick ratio of 1.40, a current ratio of 2.44 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $4.99 billion, a PE ratio of 36.65, a price-to-earnings-growth ratio of 3.42 and a beta of 0.89. Balchem Corporation has a fifty-two week low of $145.70 and a fifty-two week high of $186.03. The stock has a fifty day simple moving average of $163.15 and a 200 day simple moving average of $162.65.
Balchem (NASDAQ:BCPC - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.25 by ($0.03). The business had revenue of $250.52 million during the quarter, compared to analyst estimates of $245.70 million. Balchem had a return on equity of 12.01% and a net margin of 14.16%. The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.03 earnings per share. As a group, research analysts predict that Balchem Corporation will post 4.64 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. HC Wainwright set a $180.00 price target on Balchem and gave the company a "buy" rating in a report on Monday, April 28th. Wall Street Zen cut Balchem from a "buy" rating to a "hold" rating in a research note on Wednesday, May 21st.
Read Our Latest Analysis on BCPC
Balchem Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Further Reading

Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.